IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Lonza to Acquire Stake in German Biotech Firm

11:58 PM MDT | October 22, 2009 | Deepti Ramesh

Lonza says it has signed an investment agreement, including a right of first refusal for the commercial production of products, with innovative biotechnology company Cilian (Münster, Germany).  Cilian uses the abilities of ciliates, eukaryotic single-cell micro-organisms, specifically the strain tetrahymena thermophila, for the production of therapeutic proteins and nutritional ingredients. Lonza owns a number of patents and patent applications in the field of tetrahymena thermophila and will transfer these patents and patent applications to Cilian. In...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa